Lv51
1192 积分 2022-10-10 加入
Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α‐positive ovarian cancer: Justification of therapeutic dose regimen
12天前
已完结
A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer
13天前
已完结
Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial
13天前
已完结
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
13天前
已完结
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
13天前
已完结
Exposure–Efficacy Analysis of Asciminib in Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase
14天前
已完结
Bayesian optimal interval designs for phase I clinical trials
28天前
已完结
A Comparative Study of Bayesian Optimal Interval (BOIN) Design With Interval 3 + 3 (i3 + 3) Design for Phase I Oncology Dose-Finding Trials
28天前
已完结
Accuracy, Safety, and Reliability of Novel Phase I Trial Designs
28天前
已完结
Characterization of therapeutic mAb charge heterogeneity by iCIEF coupled to mass spectrometry (iCIEF–MS)
1个月前
已完结
皖公网安备34019202002308
